Guggenheim Initiates Coverage On Boundless Bio with Buy Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and a price target of $24.

April 22, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim initiated coverage on Boundless Bio with a Buy rating and set a price target of $24.
The initiation of coverage by Guggenheim with a Buy rating and a price target significantly above the current trading price is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100